Browse > Article
http://dx.doi.org/10.3904/kjim.2015.195

Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria  

Choi, Won-Sun (Department of Allergy and Clinical Immunology, Ajou University School of Medicine)
Lim, Eun-Soo (Department of Allergy and Clinical Immunology, Ajou University School of Medicine)
Ban, Ga-Young (Department of Allergy and Clinical Immunology, Ajou University School of Medicine)
Kim, Ji-Hye (Department of Allergy and Clinical Immunology, Ajou University School of Medicine)
Shin, Yoo-Seob (Department of Allergy and Clinical Immunology, Ajou University School of Medicine)
Park, Hae-Sim (Department of Allergy and Clinical Immunology, Ajou University School of Medicine)
Ye, Young-Min (Department of Allergy and Clinical Immunology, Ajou University School of Medicine)
Publication Information
The Korean journal of internal medicine / v.33, no.1, 2018 , pp. 185-192 More about this Journal
Abstract
Background/Aims: Chronic urticaria (CU) is a common skin disorder characterized by wheals and pruritus lasting more than 6 weeks. Due to its long duration and changeable symptoms, the quality of life (QOL) of patients with CU can be impaired substantially. We evaluated the CU-QOL, a previously validated CU-specific QOL measure, and investigated factors influencing QOL in chronic spontaneous urticaria (CSU) patients. Methods: A hospital-based cross-sectional study was performed on 390 adult patients diagnosed with CSU from March 2009 to December 2012 at the Allergy and Clinical Immunology Clinic at Ajou University Hospital. The CU-QOL questionnaire, urticaria activity score (UAS), combined angioedema, and serum total immunoglobulin E (IgE) levels were investigated. Results: The average CU-QOL score obtained from the questionnaire was 70.6 (of 100 points). The CU-QOL scores correlated significantly with the UAS, particularly with the 15-point UAS (UAS-15; coefficient -0.532, p < 0.01) rather than the 6-point UAS (-0.502, p < 0.01). The patients presenting with angioedema and urticaria had poorer scores in the urticaria symptom domain than those with urticaria alone (37.4 vs. 46.9, p = 0.004). Log-transformed serum total IgE levels correlated significantly with CU-QOL (-0.131, p < 0.05). Multivariate regression models indicated that severe CU (UAS-15 score ${\geq}13$), log (total IgE), and the presence of angioedema were significant predictors of impaired CU-QOL (< 85 points). Conclusions: CU has a substantial negative impact on QOL. The assessment of UAS-15, total IgE, and the presence of angioedema can be useful to predict QOL of the patients with CSU.
Keywords
Urticaria; Chronic; Quality of life; Angioedema; Immunoglobulin E;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924-935.   DOI
2 Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res 2012;4:326-331.   DOI
3 Nam YH, Kim JH, Jin HJ, et al. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res 2012;4:357-361.   DOI
4 Kessel A, Helou W, Bamberger E, et al. Elevated serum total IgE: a potential marker for severe chronic urticaria. Int Arch Allergy Immunol 2010;153:288-293.   DOI
5 Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2015;135:337-342.   DOI
6 Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy 2008;63:777-780.   DOI
7 O'Donnell BF. Urticaria: impact on quality of life and economic cost. Immunol Allergy Clin North Am 2014;34:89-104.   DOI
8 Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the angioedema activity score. Allergy 2013;68:1185-1192.
9 Ye YM, Jang GC, Choi SH, et al. KAAACI Work Group report on the management of chronic urticaria. Allergy Asthma Respir Dis 2015;3:3-14.   DOI
10 Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014;69:868-887.   DOI
11 Saini SS. Chronic spontaneous urticaria: etiology and pathogenesis. Immunol Allergy Clin North Am 2014;34:33-52.   DOI
12 O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197-201.   DOI
13 Engin B, Uguz F, Yilmaz E, Ozdemir M, Mevlitoglu I. The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2008;22:36-40.
14 Hashiro M, Okumura M. Anxiety, depression and psychosomatic symptoms in patients with atopic dermatitis: comparison with normal controls and among groups of different degrees of severity. J Dermatol Sci 1997;14:63-67.   DOI
15 Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria: a GA(2)LEN task force report. Allergy 2011;66:317-330.   DOI
16 Ozkan M, Oflaz SB, Kocaman N, et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2007;99:29-33.   DOI
17 Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005;60:1073-1078.   DOI
18 Ye YM, Park JW, Kim SH, et al. Clinical evaluation of the computerized chronic urticaria-specific quality of life questionnaire in Korean patients with chronic urticaria. Clin Exp Dermatol 2012;37:722-728.   DOI
19 Ye YM, Jin HJ, Hwang EK, et al. Co-existence of chronic urticaria and metabolic syndrome: clinical implications. Acta Derm Venereol 2013;93:156-160.   DOI
20 Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014;133:1365-1372.   DOI
21 Baiardini I, Bousquet PJ, Brzoza Z, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy 2010;65:290-295.   DOI
22 Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010;35:869-873.   DOI
23 Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004;59:869-873.   DOI
24 Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999;140:667-671.   DOI
25 Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy 2012;67:1289-1298.   DOI